新股消息 | 泰德医药港股IPO招股书失效

Group 1 - The core viewpoint of the article is that 泰德医药 (Tide Pharmaceutical) is preparing for its IPO in Hong Kong, with a submission date of December 6, 2024, and the prospectus will expire on June 6, 2025, with Morgan Stanley and CITIC Securities as joint sponsors [1] - 泰德医药 provides a full-cycle service from early discovery, preclinical research, clinical development to commercial production, focusing on peptide-based global CRDMO market [2] - The company primarily offers CRO services for peptide NCE discovery synthesis and CDMO services for peptide CMC development and commercial production, emphasizing API provision rather than finished drugs [2] Group 2 - 泰德医药 has established stable customer relationships in over 50 countries, including major markets such as China, the USA, Japan, Europe, South Korea, and Australia, providing services compliant with global regulatory standards for peptide drug development and production [2] - As of December 31, 2024, 泰德医药 has a broad project pipeline, including 1,217 ongoing CRO projects and 332 ongoing CDMO projects, strategically focusing on GLP-1 pipeline development [3] - The company is engaged in nine NCE GLP-1 molecular development projects with seven clients, developing oral and/or injectable GLP-1 molecular products [3]